Session » SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Date: Saturday, November 12, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 0331

Anti-dsDNA Antibodies by Multiplex Flow Immunoassay and Critihidia Luciliae Assays in NYU Lupus Registry: Discordance, Association with Nephritis, and Disease Flare Predictive Value

1:00PM-3:00PM: Abstract Number: 0322

Are Virtual Cognitive Assessments Comparable to In-person Assessments in a Systemic Lupus Erythematosus Cohort?

1:00PM-3:00PM: Abstract Number: 0330

Assessing the Utility of the Montreal Cognitive Assessment as a Screening Tool for Cognitive Impairment in Patients with SLE Using a Bayesian Item-Response Theory Model

1:00PM-3:00PM: Abstract Number: 0333

Autoantibody Trajectories Associate with Classification and Treatment Response in Lupus Nephritis

1:00PM-3:00PM: Abstract Number: 0340

Birth Order Is a Risk Factor for Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0341

Clinical Applications of Urine SERPINC1/ORM1 in MRL-lpr Lupus Nephritis-Prone Mice

1:00PM-3:00PM: Abstract Number: 0324

Comparison of NCounter® and BioFire® Technologies for the Measurement of Type I Interferon Signature

1:00PM-3:00PM: Abstract Number: 0339

Corneal Confocal Microscopy: A Potential Ophthalmic Imaging Biomarker of Neurodegeneration for Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0318

Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data

1:00PM-3:00PM: Abstract Number: 0337

Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0319

Factors Associated with Worsening Interstitial Fibrosis/Tubular Atrophy in Lupus Nephritis Patients Undergoing Repeat Kidney Biopsy

1:00PM-3:00PM: Abstract Number: 0317

Full Characterization of the Three Pathways of Complement System in Patients with Systemic Lupus Erythematosus: Relation to Disease Expression

1:00PM-3:00PM: Abstract Number: 0323

Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group

1:00PM-3:00PM: Abstract Number: 0321

M-Phase Phosphoprotein 1 (MPP-1) Autoantibodies as a Potential Biomarker for Cranial Neuropathies in an International SLE Inception Cohort

1:00PM-3:00PM: Abstract Number: 0336

Machine Learning Approach for the Prediction of Lupus Nephritis Renal Flares Using Polygenic Risk Score and Electronic Health Record

1:00PM-3:00PM: Abstract Number: 0326

Mapping Anti-Mitochondrial Antibodies over Time in a Lupus Inception Cohort

1:00PM-3:00PM: Abstract Number: 0320

Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study

1:00PM-3:00PM: Abstract Number: 0342

Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements

1:00PM-3:00PM: Abstract Number: 0335

Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile

1:00PM-3:00PM: Abstract Number: 0325

Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution

1:00PM-3:00PM: Abstract Number: 0334

Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

1:00PM-3:00PM: Abstract Number: 0328

Predicting Progression from Undifferentiated to Definitive Connective Tissue Diseases: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 0329

Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug Responses, Symptomatology and Disease Progression

1:00PM-3:00PM: Abstract Number: 0327

SMART-SLE: Serology Monitoring and Repeat Testing in Systemic Lupus Erythematosus

1:00PM-3:00PM: Abstract Number: 0332

Soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in Cerebrospinal Fluid Relating to Development of Diffuse Psychiatric/Neuropsychological Syndromes in Patients with Systemic Lupus Erythematosus (diffuse NPSLE)

1:00PM-3:00PM: Abstract Number: 0338

Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].